 |
|
2009³â 10¿ù 8ÀÏ (¸ñ) : D1 |
Á¦1ȸÀÇÀå |
Á¦2ȸÀÇÀå |
Á¦3ȸÀÇÀå |
Á¦4ȸÀÇÀå |
Á¦5ȸÀÇÀå |
Á¦6ȸÀÇÀå |
Á¦7ȸÀÇÀå |
ÄÁº¥¼Ç¼¾Å¸1Ãþ |
| 10:30-12:30 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)1
1-5 °Á¤Ã¤,±è°æ¼ö
6-10 ±èÁ¤Çö,ȲÁø¿ë
|
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)2
21-25 ¹Ú¿µ¹è,¾È¿µ±Ù
26-30 ±ÇÇöö,ÀÌ»ó°ï
|
ÁßÀç½Ã¼ú1
41-45 Á¶¸íÂù,¹ÚÁ¾¼±
46-50 ¹Ú½ÂÁ¤,¹ÚÇå½Ä |
½ÉÆ÷Áö¿ò3 -ºÎÁ¤¸Æ-
Á¶Á¤°ü,À̸¸¿µ/±èÀ¯È£,±èÀ±³â |
½ÉÆ÷Áö¿ò4 -¿µ»ó-
±èÀ±Çö,À̰æÇÑ |
±âÃÊ¿¬±¸1
87-91 °í±¤°ï,ÀÓµµ¼±
92-96 ±è´ö°æ,¹é»óÈ« |
¼Ò¾Æ1
±¸¿¬&Key Note
115-118 ±ÇÅÂÂù,±èöȣ
| Æ÷½ºÅÍ ¹ßÇ¥ 1
10:30-18:00
(1~97) |
| 12:30-14:00 |
Satellite Symposium 1 -»ç³ëÇǾƺ¥Æ¼½º-
±èÀçÇü,±è¿µÁ¶ |
Satellite Symposium 2 -Çѹ̾àǰ-
Á¶½Â¿¬,±èöȣ |
Satellite Symposium 3 -´ÙÀÌÀÌÂî»êÄì & ´ë¿õÁ¦¾à-
½ÉºÀ¼·,±è´ö°æ |
Satellite Symposium 4
-µ¿¾ÆÁ¦¾à-
È«ÅÃÁ¾,Á¶¸íÂù |
|
|
½ÉÆ÷Áö¿ò5-1 -¼Ò¾Æ½ÉÀå-
³ëÁ¤ÀÏ,ÀÌÁÖ¿ø |
| 14:00-15:30 |
Clinical Research Award1
1-6 ÀüÀº¼®,±èµ¿¿î/½É»çÀ§¿ø:±ÇÁØ,±è¿µ±Ç,±è¿µ´ë,ÀüÈñ°æ,Çö¹Î¼ö
|
Clinical Research Award2
7-12 ¿Àº´Èñ,Â÷ÅÂÁØ/½É»ç:¹Ú´ë±Õ,¼ÛÀç°ü,¿Àµ¿Áø,伺ö,ȲÈï°ï
|
½ÉÆ÷Áö¿ò1
-ÇãÇ÷¼º½ÉÁúȯ-
½Å¿µ¿ì,·ù¿Õ¼º |
½ÉºÎÀü1
51-54 ±è±â½Ä,±èÀçÁß
55-58 ¹é»óÈ«,ÃÖµ¿ÁÖ |
ÃÊÀ½ÆÄ1
69-72 Àå°æ½Ä,¼Õ´ë¿ø
73-76 Á¤»ó¸¸,±è¼ø±æ |
ºÎÁ¤¸Æ1
97-100 ±è¼º¼ø,ÃÖÀμ®
101-104 ±èÀ±³â,°ûÃæÈ¯ |
¼Ò¾Æ2
±¸¿¬&Key Note
119-122 ¹Ú¿µºÀ,À̱¤¼÷ |
| 15:30-16:00 |
Coffee Break |
Æ÷½ºÅͱ¸¿¬ 1 15:30-16:30
(1~6)
(7~12)
ÀüµÎ¼ö,Á¤°æÅÂ
|
| 16:00-18:00 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)3
11-15 ±Ç¿µÁÖ,¹Ú½ÃÈÆ
16-20 ¿Àµ¿ÁÖ,³ªµæ¿µ |
ÁßÀç½Ã¼ú2
31-35 ¹Ú¼º¿í,ÀÓµµ¼±
36-40 È«ÅÃÁ¾,ÀÌöȯ |
½ÉÆ÷Áö¿ò2 - ±âÃÊ-
¹ÚÁ¤ÀÇ,±èÄ¡Á¤ |
½ÉºÎÀü2
59-63 ±è¿µ±Ç,¹Ú½Â¿ì
64-68 ¼È«¼®,ÀüÀº¼® |
ÃÊÀ½ÆÄ2
77-81 À强±¹,±ÇÁØ
82-86 ¹ÚÁ¾Ãá,À±È£Áß |
ºÎÁ¤¸Æ2
105-109 Á¶¿ë±Ù,³²±âº´
110-114 ½Åµ¿±¸,Â÷ÅÂÁØ |
½ÉÆ÷Áö¿ò5-2 Special Lecture and Symposium
¹ÚÀμ÷,ÀÌ»óÈ£ |
|
|
2009³â 10¿ù 9ÀÏ(±Ý) : D2
07:00-08:00 ÆòÀÇ¿øÈ¸ (ÄÁº¥¼Ç¼¾ÅÍ 3Ãþ ´ÙÀ̾ƸóµåȦ) |
| Á¦1ȸÀÇÀå |
Á¦2ȸÀÇÀå |
Á¦3ȸÀÇÀå |
Á¦4ȸÀÇÀå |
Á¦5ȸÀÇÀå |
Á¦6ȸÀÇÀå |
Á¦7ȸÀÇÀå |
ÄÁº¥¼Ç¼¾Å¸ 1Ãþ |
| 08:00-09:30 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)4
123-126 ÀÌÀç¿ì,±èº´¿Á
127-130 ÀÌ¸í¹¬,±è»ó¿í |
ÁßÀç½Ã¼ú3
157-160 ±è¼º±¸,À̽Âȯ
161-164 Á¤¸íÈ£,Á¶º´·Ä |
½ÉÆ÷Áö¿ò6 -°íÇ÷¾Ð-
ÀüÀçÀº,±èöȣ |
½ÉÆ÷Áö¿ò8 -¿Ü°ú-
ÀÌ¿µÅ¹,ÀÌÀç¿ø |
ÃÊÀ½ÆÄ3
207-210 Á¤³²½Ä,±è¿øÈ£
211-214 Á¤Áø¿ø,½Å±æÀÚ |
ºÎÁ¤¸Æ3
241-244 ¿Àµ¿Áø,¿À¼¼ÀÏ
245-248 ±èÀ¯È£,±è´ë°æ |
¼Ò¾Æ3
±¸¿¬&Key Note
273-276 ÀÌ»ó¹ü,¹Ú¿µÈ¯ |
Æ÷½ºÅÍ ¹ßÇ¥ 2
08:00-18:00
(98~199) |
| 09:30-10:00 |
Coffee Break |
Æ÷½ºÅͱ¸¿¬ 2
09:00-10:00
(13~18)
(19~24)
ÀÌÀç¿õ,À¯±âµ¿ |
| 10:00-12:00 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)5
131-135 Á¶½Â¿¬,ÃÖµ¿ÁÖ
136-140 Çã½ÂÈ£,Áøµ¿±Ô |
ÁßÀç½Ã¼ú4
165-169 Á¤¿í¼º,±è¸í°ï
170-174 ÇѱԷÏ,ÀÌ»óÈÆ |
ÀþÀº1(±âÃÊ)
1-5 ¹ÚÁ¤ÀÇ,±è°æ¼ö/½É»ç:±è´ö°æ,·ù¿Õ¼º,¼È«¼®,Á¤À͸ð,ÇѱâÈÆ
|
ÀþÀº2(ÀÓ»ó)
6-10 ÀÌ¸í¹¬,¹Úâ±Ô/½É»ç:°¼®¹Î,±èÄ¡Á¤,¹ÚÁ¤¹è,ÀÓµµ¼±,ÀÓ¼¼Áß
|
¿µ»ó1
215-224 ÃÖ¿¬Çö,Á¤Çؾï
|
ºÎÁ¤¸Æ4
249-253 Á¶Á¤°ü,ÃÖ±âÁØ
254-258 ±è¿µÈÆ,À̹®Çü |
¼Ò¾Æ4
Special Lecture&±¸¿¬&Key Note
277-282 ÀÌÇØ¿ë,±è³²¼ö |
| 12:00-12:40 |
Plenary Session 1 (1~3ȸÀÇÀå) |
| 13:00-14:30 |
Satellite Symposium 5
-¾Æ½ºÆ®¶óÁ¦³×Ä«-
¹ÚÁ¤ÀÇ,À¯±ÔÇü
|
Satellite Symposium 6
-Á¾±Ù´ç-
±èÀçÇü,ÀÌ¸í¹¬ |
Satellite Symposium 7
-Çѱ¹ÈÀÌÀÚ-
½Â±â¹è,±èÈ¿¼ö |
Satellite Symposium 8 -Çѱ¹³ë¹ÙƼ½º-
¿Àº´Èñ,伺ö |
Satellite Symposium 9 -Çѱ¹¿ÀÃ÷Ä«Á¦¾à-
Á¤³²½Ä,¹Ú¼º¿í |
ÀÇ·á±â±â ¿¬¼ö°Á |
°£Çà¿öÅ©¼¥
Çã¼±,À±È£Áß |
| 14:30-16:00 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)6
141-144 ±èµ¿¼ö,±è¸í¾Æ
145-148 ÀÓÁ¾À±,À̰ÇÁÖ |
ÁßÀç½Ã¼ú5
175-178 Àå¾ç¼ö,äÀÎÈ£
179-182 ʽÂÁ¦,ÃÖµ¿ÈÆ |
ÁßÀç½Ã¼ú7
191-194 °íÀç±â,±èÈñ¿
195-198 À±Á¤ÇÑ,Çö¹Î¼ö |
½ÉÆ÷Áö¿ò9 -Ç÷°ü-
¿Àº´Èñ,±è±â½Ä |
¿µ»ó2
225-232 ÀÌ»óö,±èÅÂÈÆ |
°íÇ÷¾Ð1
259-265 Á¶¸íÂù,È«°æ¼ø |
ÁöÁú´ë»çÁúȯ
283-289 ½ÅÇöÈ£,±è»óÇö |
Æ÷½ºÅͱ¸¿¬ 3 15:30-16:30
(25~32)
(33~36)
¼ºÁöµ¿,ÀÓ»ó¿í
|
| 16:00-16:30 |
Coffee Break |
| 16:30-18:00 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)7
149-152 ½ÅÀͱÕ,Â÷±¤¼ö
153-156 ±ÇÇõ¹®,Àü±¹Áø |
ÁßÀç½Ã¼ú6
183-186 ±èÈ¿¼ö,È«¹ü±â
187-190 ½É¿øÈì,°í¿µ¿± |
½ÉÆ÷Áö¿ò7 -½ÉºÎÀü-
ÀÌ¸í¹¬,À¯±ÔÇü |
±âÃÊ¿¬±¸2
199-202 ÇѱâÈÆ,¹ÚÇö¿µ
203-206 ¿À±¸ÅÃ,À̹«¿ë |
¿µ»ó3
233-240 ±è¾ç¹Î,ÃÖº´¿í |
°íÇ÷¾Ð2
266-272 ¹Úâ±Ô,ÀÓ¼¼Áß |
¿Ü°ú
290-296 ±è±âºÀ,ÀÌ¿µÅ¹ |
|
|
|
2009³â 10¿ù 10ÀÏ (Åä) : D3 |
| Á¦1ȸÀÇÀå |
Á¦2ȸÀÇÀå |
Á¦3ȸÀÇÀå |
Á¦4ȸÀÇÀå |
Á¦5ȸÀÇÀå |
Á¦6ȸÀÇÀå |
Á¦7ȸÀÇÀå |
ÄÁº¥¼Ç¼¾Å¸ 1Ãþ |
| 08:30-10:30 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)8
297-301 ÁÖ½ÂÀç,À̳²È£
302-306 ¹Ú±Ý¼ö,Áø½Â¿ø |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)9
317-321 ±è¿µÁ¶,°íÃæ¿ø
322-326 ±è¿µ´ë,À̼ºÀ± |
ÁßÀç½Ã¼ú8
337-341 ½Â±â¹è,±èµÎÀÏ
342-346 ±èÁ¾Áø,Â÷ÅÂÁØ |
ÃÊÀ½ÆÄ4
357-361 ÀÌÀç¿ì,¹Ú¼ºÈÆ
362-366 ±è±Ç»ï,±è¿Ï |
ºÎÁ¤¸Æ5
367-371 ³ëÅÂÈ£,±èÁؼö
372-376 À̸¸¿µ,À̸í¿ë |
±âŸÀÓ»óÁúȯ1
377-381 ¹ÚÀÇÇö,ÀÓ¼¼Áß
382-386 ÀüÀçÀº,¹Ú½Â¿ì |
±âÃÊ¿¬±¸3
397-401 Àå¾ç¼ö,±è¹«Çö
402-406 °í±Ô¿µ,±èÈ¿¼ö |
Æ÷½ºÅÍ ¹ßÇ¥ 3
08:30~15:30
(200~292) |
| 10:30-11:00 |
Coffee Break |
Æ÷½ºÅͱ¸¿¬4
10:00~11:00
(37~42)
(43~48)
¾ÈÁ¤Ãµ,Á¶¿íÇö
|
| 11:00-11:40 |
Plenary Session 2 (1~3ȸÀÇÀå) |
| 11:40-13:30 |
ÃÑ È¸ (Á¡½É) 1-3ȸÀÇÀå |
| 13:30-15:30 |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)10
307-311 ±è±Ç¹è,°í¿µ¿±
312-316 È«°æÇ¥,Çã½ÂÈ£ |
ÇãÇ÷¼º½ÉÇ÷°üÁúȯ (°üµ¿¸ÆÁúȯ)11
327-331 ¼ºÀÎȯ,äÁ¦°Ç
332-336 Â÷µ¿ÈÆ,ÃÖ¿µÁø |
ÁßÀç½Ã¼ú9
347-351 ¾ÈÅÂÈÆ,È«¸í±â
352-356 ±è¹«Çö,ÀüÈñ°æ |
½ÉÆ÷Áö¿ò10 -ÁßÀç½Ã¼ú-
¹Ú¿µ¹è,ʽÂÁ¦ |
½ÉÆ÷Áö¿ò11 -½ÉÃÊÀ½ÆÄ-
½É¿ÏÁÖ,¼ÛÀç°ü |
±âŸÀÓ»óÁúȯ2
387-391 ±èö¹Î,ÃÖÁö¿ë
392-396 Á¶ÁÖÈñ,³ª½Â¿î |
±âÃÊ¿¬±¸4
407-411 Á¶¸íÂù,¼È«¼®
412-416 Á¤À͸ð,¹ÚÇö¿µ |
|
|
* 1~3ȸÀÇÀå: ÄÁº¥¼Ç 4Ãþ
* 4~5 ÄÁº¥¼Ç 3Ãþ(¿¡¸Þ¶öµåA,B)
* 6~7ȸÀÇÀå: º»°ü 2Ãþ (±×·£µåº¼·ë)
| Plenary Session |
|
| 2009³â 10¿ù 9ÀÏ (±Ý) |
ÁÂÀå: ½ÉºÀ¼· |
| 12:00-12:40 |
Can Stent Thrombosis After Drug Eluting Stents be Prevented?
|
David P. Faxon/ USA |
| 2009³â 10¿ù 10ÀÏ (Åä) |
ÁÂÀå: ¹Ú¿µ¹è |
| 11:00-11:40 |
Acute Coronary Syndromes: Pathophysiology and Management of an Inflammatory Disease |
Thomas F. Luscher/ Switzerland |
|
|
| ½ÉÆ÷Áö¿ò |
|
| 2009³â 10¿ù 8ÀÏ (¸ñ) |
| Á¦ 3ȸÀÇÀå |
| 1. ÇãÇ÷¼º½ÉÁúȯ |
| 14:00-15:30 |
Platelet: Biology, Assay & Resistance |
ÁÂÀå: ½Å¿µ¿ì, ·ù¿Õ¼º |
| 14:00-14:20 |
1. Biology of Platelet
|
ÁÖ½ÂÀç/Á¦ÁÖÀÇ´ë |
| 14:20-14:40 |
2. Assay of Platelet Function & Cut Off Value of Resistance Against Anti-platelet Drugs
|
Á¤¿µÈÆ/°æ»óÀÇ´ë |
| 14:40-15:00 |
3. Pharmaco-genetics for Resistance Against Anti-Platelet Drugs
|
¼Á¤¿ø/¼¿ïÀÇ´ë |
| 15:00-15:20 |
4. Clinical Implication of Resistance Against Anti-Platelet Drugs
|
ÇÑÁÖ¿ë/¼º±Õ°üÀÇ´ë |
| 15:20-15:30 |
5. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: ±è¹«Çö, ¹Ú°æ¿ì, À±Á¤ÇÑ, Çö¹Î¼ö |
|
| 2. ±âÃÊ |
| 16:00-18:00 |
Recent Change in Basic Cardiovascular Research (Review Course) |
ÁÂÀå: ¹ÚÁ¤ÀÇ, ±èÄ¡Á¤ |
| 16:00-16:25 |
1. ROS, Free Fatty Acids and diabetic vascular complication
|
¹ÚÁß¿/¿ï»êÀÇ´ë |
| 16:25-16:50 |
2. Ischemic Pre-conditioning and Post-conditioning
|
±ÇÇöö/¼º±Õ°üÀÇ´ë |
| 16:50-17:15 |
3. Vascular Calcification : Active and Regulated Process in Vascular Disease
|
Á¶ÇöÀç/¼¿ïÀÇ´ë |
| 17:15-17:40 |
4. Vascular Aging and Arteriosclerosis
|
±èÀç·æ/¿µ³²ÀÇ´ë |
| 17:40-18:00 |
5. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î:¹ÚÇö¿µ, ¹é»óÈ«, ÇѱâÈÆ, Á¤À͸ð |
|
| Á¦ 4ȸÀÇÀå |
| 3. ºÎÁ¤¸Æ |
| 10:30-11:30 |
AF, from In-silico to Bedside |
ÁÂÀå: Á¶Á¤°ü, À̸¸¿µ |
| 10:30-10:48 |
1. Non-linear Dynamics in Fibrillation
|
À̰æÁø/°í·Á´ëÇб³ |
| 10:48-11:06 |
2. Spectrum Analysis in AF |
¿À¼¼ÀÏ/¼¿ïÀÇ´ë |
| 11:06-11:24 |
3. Ablation Strategy for Chronic AF
|
³²±âº´/¿ï»êÀÇ´ë |
| 11:24-11:30 |
4. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î : °ûÃæÈ¯, ±è³²È£ |
|
| 11:30-12:30 |
VT/ VF, Basics and Application |
ÁÂÀå: ±èÀ¯È£, ±èÀ±³â |
| 11:30-11:48 |
1. LV and RV Anatomy for the Electrophysiologist |
¼Á¤¿í/¼¿ïÀÇ´ë |
| 11:48-12:06 |
2. Pathology of VT/VF in Structural Heart Disease |
Á¶¿ë±Ù/°æºÏÀÇ´ë |
| 12:06-12:24 |
3. VT Ablation in Prior Myocardial Infarction |
Chun Hwang/USA |
| 12:24-12:30 |
4. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: ¹ÚÈñ³², Â÷ÅÂÁØ |
|
| Á¦ 5ȸÀÇÀå |
| 4. ¿µ»ó |
| 10:30-12:30 |
Recent Advancements in Cardiac Imaging |
ÁÂÀå: ±èÀ±Çö, À̰æÇÑ |
| 10:30-10:50 |
1. Recent Updates in Cardiac MDCT & MRI |
Ã߱⼮/ºÎ»êÀÇ´ë |
| 10:50-11:10 |
2. Fusion of Myocardial SPECT and CT Angiography to Diagnose Ischemic Heart Disease
|
ÀÓ¼®ÅÂ/ÀüºÏ´ëÇб³ |
| 11:10-11:30 |
3. Cardiac MRI for Ischemic Heart Disease
|
±è¿µÁø/¿¬¼¼ÀÇ´ë |
| 11:30-11:50 |
4. Imaging of Atheromatous Plaque Using Nuclear Medicine Technique
|
¿©Á¤¼®/µ¿±¹´ëÇб³ |
| 11:50-12:10 |
5. Post-treatment Follow-up CTCA
|
ÀüÀºÁÖ/¼¿ïÀÇ´ë |
| 12:10-12:30 |
6. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: °¿øÁØ, ¿ëȯ¼®, Á¤Á¤ÀÓ, ÃÖÁØ¿µ |
|
| Á¦ 7ȸÀÇÀå |
| 5. ¼Ò¾Æ½ÉÀå(1) |
| 12:30-14:00 |
Symposium 1 |
|
| 12:30-14:00 |
Childhood Origin of Atherosclerosis |
ÁÂÀå: ³ëÁ¤ÀÏ, ÀÌÁÖ¿ø |
| 12:30-12:50 |
1. Childhood Origin of Atheroscleoris
|
È«¿µ¹Ì/ÀÌÈÀÇ´ë |
| 12:50-13:10 |
2. Assessment of Endothelial Function and Its Clinical Application in Childhood
|
Áø¼±¹Ì/À»ÁöÀÇ´ë |
| 13:10-13:30 |
3. Treatment Strategies for Dyslipidemia in Childhood
|
ÇÑÁöȯ/°¡Å縯ÀÇ´ë |
| 13:30-14:00 |
4. ÅäÀÇ |
ÆÐ³Î: ¼Û¹Î¼·, ÇãÁØ, À±½Å¿ø(Áß¾Ó) |
|
| 16:00-18:00 |
Special Lecture and Symposium 2 |
|
| 16:00-18:00 |
CHF: CHD Associated or Recent Advance |
ÁÂÀå: ¹ÚÀμ÷, ÀÌ»óÈ£ |
| 16:00-16:30 |
1. Revisit to Some Basics of Blood Pressure
|
Myung K. Park/USA |
| 16:30-16:50 |
2. How Can We Integrate the Biomarker and Its Application in Pediatric CHF?
|
±è¿µÈÖ/¿ï»êÀÇ´ë |
| 16:50-17:10 |
3. Myocardial Failure in Fontan Circulation
|
±è¼öÁø/ºÎõ¼¼Á¾º´¿ø |
| 17:10-17:30 |
4. Surgical Management as a Bridge to Transplantation in Children with Refractory CHF
|
¾çÁöÇõ/¼º±Õ°üÀÇ´ë |
| 17:30-18:00 |
5. ÅäÀÇ |
Panel: ¹ÚÁ¤ÁØ, °À̼®, Çö¸íö |
|
| Key Note and Free Paper |
|
| 10:30-11:30 |
Key Note 1-3 & Free Paper (1) |
ÁÂÀå: ÀÌÈïÀç, ±è¿ëÁø |
| 10:30-10:50 |
1. Late Hypertension in Patients with Successfully Repaired CoA
|
±è±â¹ü/¼¿ïÀÇ´ë |
| 10:50-11:10 |
2. Brain Outcome After Surgery for CHD: Patient and Perioperative Factors
|
äÁ¾Èñ/¼¿ïÀÇ´ë |
| 11:10-11:30 |
3. Surgical Strategies to Minimize Morbidity in OR and ICU
|
À±ÅÂÁø/¿ï»êÀÇ´ë |
| 11:30-12:30 |
Free Paper(1) |
ÁÂÀå: ±ÇÅÂÂù, ±èöȣ Panel: ¼Õ¼¼Á¤, ¼ÛÁø¿µ, ±è½ÃÈ£ |
|
| 14:00-15:30 |
Key Note 4-5 & Free Paper (2) |
ÁÂÀå: ±è¼ºÈ£(Á¦ÁÖÇѶ󺴿ø) |
| 14:00-14:20 |
4. What a hot in intervention
|
ÃÖÀ翵/¿¬¼¼ÀÇ´ë |
| 14:20-14:40 |
5. ¿Ü±¹ ¼±Ãµ¼º ½ÉÀ庴 ȯÀÚ Áö¿ø ÇöȲ ºÐ¼® ¹× ÇâÈÄ Áö¿ø ¹æ½Ä¿¡ ´ëÇÑ Á¦¾È
|
¹ÚÀμ÷/¿ï»êÀÇ´ë |
| 14:40-15:30 |
Free Paper(2) |
ÁÂÀå: ¹Ú¿µºÀ, À̱¤¼÷ Panel: Á¤Á¶¿ø, ÀÌâÇÏ, Á¤¹ÌÁø |
|
|
| 2009³â 10¿ù 9ÀÏ (±Ý) |
| Á¦ 3ȸÀÇÀå |
| 6. °íÇ÷¾Ð |
| 08:00-09:30 |
Considerations in the Management of Hypertension |
ÁÂÀå: ÀüÀçÀº, ±èöȣ |
| 08:00-08:20 |
1. Hypertension with Obesity
|
±è¹Î±Ô/ÇѸ²ÀÇ´ë |
| 08:20-08:40 |
2. Hypertension with Pregnancy
|
¹®À翬/Æ÷õÁß¹®ÀÇ´ë |
| 08:40-09:00 |
3. Hypertension with Very Elderly Patients
|
±è±¤ÀÏ/¼¿ïÀÇ´ë |
| 09:00-09:20 |
4. Non-invasive Hemodynamic Test in Hypertensive Patients
|
ÇѽÂȯ/°¡ÃµÀÇ´ë |
| 09:20-09:30 |
5. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: ±èµ¿¼ö, ±èµ¿¿î, ±èÇü¼·, ¹Úâ±Ô |
|
| 7. ½ÉºÎÀü |
| 16:30-18:00 |
Challenging Issues in the Management of Chronic Heart Failure |
ÁÂÀå: ÀÌ¸í¹¬, À¯±ÔÇü |
| 16:30-16:50 |
1. Heart Failure with COPD
|
ÀüÈñ°æ/°¡Å縯ÀÇ´ë |
| 16:50-17:10 |
2. Heart Failure on Dialysis
|
ȲÁø¿ë/°æ»óÀÇ´ë |
| 17:10-17:30 |
3. How Should We Manage Blood Pressure in Heart Failure
|
Á¤¿íÁø/°¡ÃµÀÇ´ë |
| 17:30-17:50 |
4. How Should We Treat Heart Failure with Diastolic Dysfunction?
|
¹ÚÀçÇü/Ãæ³²ÀÇ´ë |
| 17:50-18:00 |
5. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: °¼®¹Î, Áøµ¿±Ô, È«±×·ç |
|
| Á¦ 4ȸÀÇÀå |
| 8. ½ÉÀåÇ÷°ü¿Ü°ú |
| 08:00-09:30 |
ECMO (Extracorporeal Membrane Oxygenation) Support |
ÁÂÀå: ÀÌ¿µÅ¹, ÀÌÀç¿ø |
| 08:00-08:20 |
1. Indication and Practical Application of ECMO
|
±èÇü¼ö/ÇѸ²´ëÇб³ |
| 08:20-08:40 |
2. Management of Complications During ECMO
|
À±¿µ³²/¿¬¼¼ÀÇ´ë |
| 08:40-09:00 |
3. PCPS in Non-surgical Conditions
|
¼Û¿µºó/¼º±Õ°üÀÇ´ë |
| 09:00-09:20 |
4. ECMO in Children
|
¹ÚÁ¤ÁØ/¿ï»êÀÇ´ë |
| 09:20-09:30 |
5. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: Á¤Ã¶Çö ,¼ÛÇö, ¹Ú°èÇö |
|
| 9. Ç÷°ü¿¬±¸È¸ |
| 14:30-16:00 |
Venous Thromboembolism |
ÁÂÀå: ¿Àº´Èñ, ±è±â½Ä |
| 14:30-14:45 |
1. Genetic Test for the Better Outcome of VTE?
|
À±¼º¼ö/¼¿ïÀÇ´ë |
| 14:45-15:00 |
2. Evolution of Anticoagulation Therapy
|
±èÀ念/¿¬¼¼¿øÁÖÀÇ´ë |
| 15:00-15:15 |
3. Interventional Treatment of VTE: Radiologic Approach
|
ÀÌÇØ±Ô/°¡Å縯ÀÇ´ë |
| 15:15-15:30 |
4. Surgical Approach of VTE
|
¹Î½Â±â/¼¿ïÀÇ´ë |
| 15:30-15:45 |
5. VTE in Pregnancy
|
¹ÚÁ¤¹è/°üµ¿ÀÇ´ë |
| 15:45-16:00 |
6. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: ±èÈñÁø, À¯»ó¿ë, À庴ö, Á¤Çؾï |
|
| Á¦ 7ȸÀÇÀå |
| 5. ¼Ò¾Æ½ÉÀå(2) |
| Special Lecture |
ÁÂÀå: ÁÖÂù¿õ |
| 10:00-10:30 |
Pediatric Cardiology: Past, Present, and Future-My Journey
|
Myung K. Park/USA |
|
| 08:00-08:40 |
Key Note 6-7 & Free Paper (3) |
ÁÂÀå: °íÀç°ï |
| 08:00-08:20 |
6. Timing and Indication for Fontan
|
ÀÌÇüµÎ/ºÎ»êÀÇ´ë |
| 08:20-08:40 |
7. Management of PA and Intracardiac Problems at the Time of the Fontan
|
¹ÚÇѱâ/¿¬¼¼ÀÇ´ë |
| 08:40-09:30 |
Free Paper(3) |
ÁÂÀå: ÀÌ»ó¹ü, ¹Ú¿µÈ¯ Panel: À¯ÀçÇö, ÀÌÀ翵, ÀÌ¿µ¼® |
|
| 10:30-10:50 |
Key Note 8 &Free Paper (4) |
ÁÂÀå: ¼º½ÃÂù |
| 10:30-10:50 |
8. Message from Longterm Outcomes in PA/VSD/MAPCAs
|
±è¿õÇÑ/¼¿ïÀÇ´ë |
| 10:50-12:00 |
Free Paper(4) |
ÁÂÀå: ÀÌÇØ¿ë, ±è³²¼ö Panel: Àå±â¿µ, ÇÑÀçÁø, À¯°æÈñ |
|
| Korean Circulation Journal ±¹Á¦ÇмúÁö·ÎÀÇ µµ¾à |
| 13:00-14:30 |
ÁÂÀå: Çã ¼±(ÇѸ²ÀÇ´ë, ÀÇÆíÇù Á¤º¸°ü¸®À§¿øÀå), À±È£Áß(´ëÇѽÉÀåÇÐȸ °£ÇàÀÌ»ç) |
| 13:00-13:50 |
1. »õ³í¹®ÀÛ¼º¹ý(Reporting Guideline)
|
±è¼ö¿µ (ÇѸ²ÀÇ´ë, ÀÇÆíÇù ÃâÆÇÀ±¸®À§¿ø) |
| 13:50-14:00 |
2. ÁúÀÇÀÀ´ä |
|
| 14:00-14:30 |
3. Korean Circulation Journal ÀÌ SCI·Î °¡´Â ±æ |
Çã ¼± (ÇѸ²ÀÇ´ë, ÀÇÆíÇù Á¤º¸°ü¸®À§¿øÀå) |
|
|
| 2009³â 10¿ù 10ÀÏ (Åä) |
| Á¦ 4ȸÀÇÀå |
| 10. ÁßÀç½Ã¼ú |
| 13:30-15:30 |
Drug Eluting Stent - A Close Look |
ÁÂÀå: ¹Ú¿µ¹è, ʽÂÁ¦ |
| 13:30-13:55 |
1. Specific Indication for DES & BMS: How to Choose
|
¾È¿µ±Ù/Àü³²ÀÇ´ë |
| 13:55-14:20 |
2. The Efficacy of DES in Tough Subsets Such as Diabetes and CKD: How Well Does It Work?
|
ÇѱԷÏ/ÇѸ²ÀÇ´ë |
| 14:20-14:45 |
3. Comparison Between? SES, PES, ZES, and EES: Is There Difference?
|
Çã½ÂÈ£/°è¸íÀÇ´ë |
| 14:45-15:10 |
4. Innovative New DES's: Are They Promising?
|
±èº´¿Á/ÀÎÁ¦ÀÇ´ë |
| 15:10-15:30 |
5. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: ±ÇÇöö, ±èÈ¿¼ö, ½Â±â¹è, Àå¾ç¼ö |
|
| Á¦ 5ȸÀÇÀå |
| 11. ½ÉÃÊÀ½ÆÄ |
| 13:30-15:30 |
Role of Echocardiography in Ischemic Heart Disease |
ÁÂÀå: ½É¿ÏÁÖ,¼ÛÀç°ü |
| 13:30-13:50 |
1. Echocardiography for Acute Chest Pain |
¹Ú½Â¿ì/¼º±Õ°üÀÇ´ë |
| 13:50-14:10 |
2. Echocardiographic Evaluation of Coronary Flow |
À±È£Áß/°¡Å縯ÀÇ´ë |
| 14:10-14:30 |
3. Stress Echocardiography: Pharmacologic vs. Exercise
|
¼ÛÁ¾¹Î/¿ï»êÀÇ´ë |
| 14:30-14:50 |
4. Contrast Echocardiography |
ÀÓ¼¼Áß/¿¬¼¼ÀÇ´ë |
| 14:50-15:10 |
5. Strain and Strain Rate Imaging in Ischemic Heart Disease |
Á¶±¸¿µ/¼¿ïÀÇ´ë |
| 15:10-15:30 |
6. Áú¹® ¹× ÅäÀÇ |
ÆÐ³Î: ¹Ú¼º¹Ì, ±è¿ì½Ä, À̰æÁø, ½ÅÁØÇÑ, À¯³²Áø |
|
|
| Satellite Symposium |
|
| 2009³â 10¿ù 8ÀÏ (¸ñ) |
| 1. »ç³ëÇǾƺ¥Æ¼½º [1ȸÀÇÀå] |
| New perspective on cardiovascular disease |
ÁÂÀå: ±èÀçÇü,±è¿µÁ¶ |
|
1. Recent Clinical Trial Data on CV Outcomes of Irbesartan in AF Patients:ACTIVE -i |
±èÈ¿¼ö/¼¿ïÀÇ´ë |
|
2. Optimal Dosing of Antiplatelet Therapy in Patients With ACS undergoing an Early Invasive Strategy: Insights From the CURRENT (OASIS 7) Trial |
David P. Faxon/USA |
|
3. Q&A |
|
|
| 2. Çѹ̾àǰ [1ȸÀÇÀå] |
| Current Issue in Antihypertensive Therapy |
ÁÂÀå: Á¶½Â¿¬,±èöȣ |
|
1. New Trend of Antihypertensive Therap
|
¹Úâ±Ô/°í·ÁÀÇ´ë |
|
2. Clinical Trial Results for Amosartan
|
Frans HH Leenen/Canada |
|
| 3. ´ÙÀÌÀÌÂî»êÄì & ´ë¿õÁ¦¾à [3ȸÀÇÀå] |
| Treatment in HTN Patients with Metabolic Syndrome |
ÁÂÀå: ½ÉºÀ¼·,±è´ö°æ |
|
1. Prevalence and Characteristics of Metabolic Syndrome in Korean Hypertension Patients
|
¹é»óÈ«/°¡Å縯ÀÇ´ë |
|
2. OMEGA Study; The Relationship Between CVD, Metabolic SYndrome and BP(TBD)
|
Tamio Teramoto/Japan |
|
| 4. µ¿¾ÆÁ¦¾à [4ȸÀÇÀå] |
| Atorvastatin Original/ Generic °£ ÀÓ»óÀû È¿°ú ºñ±³ |
ÁÂÀå: È«ÅÃÁ¾,Á¶¸íÂù |
|
1. ÀÌ»óÁöÁúÇ÷ÁõÀÇ ÃÖ½ÅÁö°ß
|
±è»óÇö/¼¿ïÀÇ´ë |
|
2. ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚ¿¡°Ô¼ Atorvastatin 20mgÀÇ Original/ Generic Á¦Ç° »çÀÌÀÇ ¾ÈÀü¼º ¹× À¯È¿¼º ºñ±³ ÀÓ»ó°á°ú
|
À±¸íÈ£/¾ÆÁÖÀÇ´ë |
|
|
| 2009³â 10¿ù 9ÀÏ (±Ý) |
| ¾Æ½ºÆ®¶óÁ¦³×Ä« [1ȸÀÇÀå] |
| Optimal Management of Cardiovascular Disase |
ÁÂÀå: ¹ÚÁ¤ÀÇ,À¯±ÔÇü |
|
1. Effective Management of Severe Hypertension with High Dose Candesartan: CEASAR Study
|
ÃÖµ¿ÈÆ/¿¬¼¼ÀÇ´ë |
|
2. The Role of Statins in Decreasing the Risk of Acute Events in a Patient with Coronary Artery Disease
|
James Liao/USA |
|
| Á¾±Ù´ç [2ȸÀÇÀå] |
| New Treatment Option for Atorvastatin |
ÁÂÀå: ±èÀçÇü,ÀÌ¸í¹¬ |
|
1. Statin Overview
|
±èµ¿¿î/ÃæºÏÀÇ´ë |
|
2. KoLipilou Study
|
±è»óÇö/¼¿ïÀÇ´ë |
|
| ÈÀÌÀÚ [3ȸÀÇÀå] |
| New Approach for Korean Patients on Statin Therapy |
ÁÂÀå: ½Â±â¹è,±èÈ¿¼ö |
|
1. Patient-tailored Statin Therapy in Achieving LDL-C Targets in Korean Patients
|
ÀÌöȯ/¿ï»êÀÇ´ë |
|
2. Case Review: Statin High Dose in Korean Patients
|
Çã½ÂÈ£/°è¸íÀÇ´ë |
|
3. Panel Discussion |
ÆÐ³Î: ±èµÎÀÏ, ÃÖµ¿ÁÖ |
|
| ³ë¹ÙƼ½º [4ȸÀÇÀå] |
| Attaining Greater BP Reductions and Organ Protection: Current Strategies and Future Priorities |
ÁÂÀå: ¿Àº´Èñ,伺ö |
|
1. A Journey to the Best ARB for Koreans
|
°´öÇö/¿ï»êÀÇ´ë |
|
2. Combination Therapy for Hypertension in High-risk Patients
|
Kenneth A. Jamerson/USA |
|
3.Q&A |
|
|
| Çѱ¹¿ÀÃ÷Ä«Á¦¾à [5ȸÀÇÀå] |
| Antiplatelet Therapy in Diabetic Cardiovascular Disease; The Appraisal of Cilostazol |
ÁÂÀå: Á¤³²½Ä,¹Ú¼º¿í |
|
1. Clinical and Prognostic Relevance of Diabetes Mellitus in Cardiovascular Disease; The Benefits of Antiplatelet Therapy to prevent Vascular Event
|
¹èÀåÈ£/°Ç¾çÀÇ´ë |
|
2. Additive or Adjunctive Role of Cilosatzol in Diabetic Patients with High Platelet REactivity After PCI
|
±è¸í°ï/°æÈñÀÇ´ë |
|
3. The Role of Cilostazol in Diabetic Patients Undergoing PCI
|
À̽Âȯ/¿ï»êÀÇ´ë |
|
4. Discussion |
ÆÐ³Î: ¼Á¤¿ø, ¾È¿µ±Ù, Á¤¿µÈÆ |
|
|
|
|
|